Dr. Wenfeng Gong 龚文锋
Chief Physician
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and comprehensive treatment of liver, gallbladder, pancreatic cancers, and hemangiomas. Specializes in minimally invasive surgeries for primary liver cancer, including laparoscopic resection, radiofrequency ablation, and ethanol injection.
Dr. Gong holds a medical doctorate in surgery and serves as academic leader in hepatobiliary, pancreatic, and splenic surgery. Research focuses on primary liver cancer, biliary and pancreatic tumors, and stones. Dr. Gong participated in multiple funded projects and received Guangxi Science and Technology Progress First Prizes in 2019 and 2017. Authored over 20 papers, including 7 SCI articles.
Name order: in Chinese the family name comes first (Gong Wenfeng). Papers usually list the name as Wenfeng Gong or Gong W.
Selected publications
41 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- ILIVER, 2026 (senior author): A cohort study on efficacy and safety of treatment modalities for resectable hepatocellular carcinoma with extrahepatic metastasis. PubMed 42960053
- Food Waterborne Parasitol, 2026 (senior author): Clonorchis sinensis promotes hepatocellular carcinoma progression via a potential PTTG1-β-catenin-c-MYC axis. PubMed 41769203
- Front Immunol, 2025 (senior author): Development of a machine learning model to predict overall survival for large hepatocellular carcinoma at BCLC stage A or B after curative hepatectomy. PubMed 41194935
- Eur J Surg Oncol, 2023 (senior author): Is hepatectomy feasible for hepatocellular carcinoma patients with clinically significant portal hypertension and beyond the Milan criteria?. PubMed 37748278
- Expert Rev Gastroenterol Hepatol, 2020 (senior author): Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma. PubMed 32552297
- Biosci Rep, 2019 (first author): Evaluation of liver regeneration and post-hepatectomy liver failure after hemihepatectomy in patients with hepatocellular carcinoma. PubMed 31383787
- Oncotarget, 2017 (first author): Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma. PubMed 28122361
- Mol Clin Oncol, 2016 (first author): Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy. PubMed 27330754
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion